CLCS
Price:
$0.6
Market Cap:
$25.16M
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, ...[Read more]
Industry
Biotechnology
IPO Date
2014-05-01
Stock Exchange
PNK
Ticker
CLCS
According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.02. This represents a change of 70.75% compared to the average of 0.01 of the last 4 quarters.
The mean historical Current Ratio of Cell Source, Inc. over the last ten years is 0.04. The current 0.02 Current Ratio has changed 6.18% with respect to the historical average. Over the past ten years (40 quarters), CLCS's Current Ratio was at its highest in in the September 2014 quarter at 0.11. The Current Ratio was at its lowest in in the June 2022 quarter at 0.00.
Average
0.04
Median
0.03
Minimum
0.01
Maximum
0.10
Discovering the peaks and valleys of Cell Source, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 220.03%
Maximum Annual Current Ratio = 0.10
Minimum Annual Increase = -98.78%
Minimum Annual Current Ratio = 0.01
Year | Current Ratio | Change |
---|---|---|
2023 | 0.01 | -60.70% |
2022 | 0.03 | 1.54% |
2021 | 0.03 | -42.54% |
2020 | 0.05 | 167.97% |
2019 | 0.02 | 52.30% |
2018 | 0.01 | -87.37% |
2017 | 0.10 | 220.03% |
2016 | 0.03 | -41.61% |
2015 | 0.06 | 80.54% |
2014 | 0.03 | -98.78% |
The current Current Ratio of Cell Source, Inc. (CLCS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0.02
5-year avg
0.03
10-year avg
0.04
Cell Source, Inc.’s Current Ratio is less than Emmaus Life Sciences, Inc. (0.14), greater than Adhera Therapeutics, Inc. (0.00), less than PolarityTE, Inc. (4.11), less than ZIVO Bioscience, Inc. (0.17), less than Pasithea Therapeutics Corp. (6.20), less than Nutriband Inc. (6.57), less than MediciNova, Inc. (18.24), less than Eliem Therapeutics, Inc. (60.41), less than Panbela Therapeutics, Inc. (0.05), less than Virpax Pharmaceuticals, Inc. (0.48), less than Revelation Biosciences, Inc. (1.10), less than Biodexa Pharmaceuticals Plc (2.16), less than Praxis Precision Medicines, Inc. (17.30), less than Cardio Diagnostics Holdings, Inc. (5.69), less than Sigilon Therapeutics, Inc. (1.78), less than Sonnet BioTherapeutics Holdings, Inc. (1.65), less than ZyVersa Therapeutics, Inc. (0.06), less than X4 Pharmaceuticals, Inc. (6.07), less than eFFECTOR Therapeutics, Inc. (1.03), less than Landos Biopharma, Inc. (4.43), less than Apexigen, Inc. (0.82), less than Navidea Biopharmaceuticals, Inc. (0.56), less than Angion Biomedica Corp. (1.74),
Company | Current Ratio | Market cap |
---|---|---|
0.14 | $1.92M | |
0.00 | $1.44K | |
4.11 | $1.78M | |
0.17 | $68.83M | |
6.20 | $3.78M | |
6.57 | $70.93M | |
18.24 | $82.40M | |
60.41 | $342.68M | |
0.05 | $1.80M | |
0.48 | $3.47M | |
1.10 | $3.19M | |
2.16 | $3.30M | |
17.30 | $1.24B | |
5.69 | $7.22M | |
1.78 | $56.22M | |
1.65 | $2.96M | |
0.06 | $1.96M | |
6.07 | $89.59M | |
1.03 | $1.88K | |
4.43 | $71.68M | |
0.82 | $9.57M | |
0.56 | $50.04K | |
1.74 | $30.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Cell Source, Inc.'s Current Ratio?
How is the Current Ratio calculated for Cell Source, Inc. (CLCS)?
What is the highest Current Ratio for Cell Source, Inc. (CLCS)?
What is the 3-year average Current Ratio for Cell Source, Inc. (CLCS)?
What is the 5-year average Current Ratio for Cell Source, Inc. (CLCS)?
How does the current Current Ratio for Cell Source, Inc. (CLCS) compare to its historical average?